Edition:
United States

Genetic Technologies Ltd (GENE.OQ)

GENE.OQ on NASDAQ Stock Exchange Capital Market

1.14USD
4:00pm EDT
Change (% chg)

$0.01 (+0.88%)
Prev Close
$1.13
Open
$1.14
Day's High
$1.14
Day's Low
$1.11
Volume
4,177
Avg. Vol
64,048
52-wk High
$2.05
52-wk Low
$0.75

Latest Key Developments (Source: Significant Developments)

Genetic Technologies Signs JV Deal With Beijing Zishan Health Consultancy
Thursday, 16 Aug 2018 12:42am EDT 

Aug 16 (Reuters) - Genetic Technologies Ltd ::CO SIGNED PROPOSED JOINT VENTURE WITH BEIJING ZISHAN HEALTH CONSULTANCY LIMITED.JV WILL BE OWNED 50 PERCENT BY GTG AND 50 PERCENT BY ZISHAN AND ITS ASSOCIATED ENTITIES.  Full Article

Genetic Technologies Says H1 Comprehensive Loss Attributable $3.3 Mln
Monday, 26 Feb 2018 05:39pm EST 

Feb 27 (Reuters) - Genetic Technologies Ltd ::H1 REVENUE FROM CONTINUING OPERATIONS - GENETIC TESTING SERVICES $97.8 MILLION VERSUS $369.1 MILLION.‍H1 COMPREHENSIVE LOSS ATTRIBUTABLE $3.3 MILLION.  Full Article

Genetic Technologies Says Eutillio​ ‍Buccilli To Step Down As CEO
Monday, 5 Feb 2018 05:46pm EST 

Feb 6 (Reuters) - Genetic Technologies Ltd ::CHANGE OF CHIEF EXECUTIVE OFFICER.EUTILLIO​ ‍BUCCILLI WILL STEP DOWN AS CHIEF EXECUTIVE OFFICER WITH IMMEDIATE EFFECT.‍KASIAN HAS BEEN APPOINTED AS ACTING CEO.  Full Article

Genetic Technologies says FY consolidated revenue $518,506
Monday, 28 Aug 2017 09:48pm EDT 

Aug 29 (Reuters) - Genetic Technologies Ltd :FY consolidated revenue from ordinary activities $518,506, down 54 percent.FY consolidated loss attributable to members $8.4 million.  Full Article

Genetic Technologies announces comprehensive review of strategic alternatives
Friday, 25 Aug 2017 05:30am EDT 

Aug 25 (Reuters) - Genetic Technologies Ltd :Genetic Technologies announces comprehensive review of strategic alternatives.Genetic Technologies Ltd - ‍strategic alternatives include business combination or strategic merger, reverse merger, sale of company or assets​.Genetic Technologies Ltd - ‍strategic alternatives also include in-licensing assets, an acquisition, or other transaction​.  Full Article